{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:14:37Z","timestamp":1760141677167,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Clinics of North America: Equine Practice"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.cveq.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T03:45:32Z","timestamp":1486007132000},"page":"87-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutics for Equine\u00a0Protozoal Myeloencephalitis"],"prefix":"10.1016","volume":"33","author":[{"given":"Nicola","family":"Pusterla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.cveq.2016.12.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetpar.2015.01.026","article-title":"An update on Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM)","volume":"209","author":"Dubey","year":"2015","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.cveq.2016.12.001_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.vetpar.2005.05.016","article-title":"Evidence to support horses as natural intermediate hosts for Sarcocystis neurona","volume":"133","author":"Mullaney","year":"2005","journal-title":"Vet Parasitol"},{"issue":"2","key":"10.1016\/j.cveq.2016.12.001_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1645\/GE-2657.1","article-title":"Endogenous transplacental transmission of Neospora hughesi in naturally infected horses","volume":"97","author":"Pusterla","year":"2011","journal-title":"J\u00a0Parasitol"},{"issue":"9","key":"10.1016\/j.cveq.2016.12.001_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/vr.149.9.269","article-title":"Suspected protozoal myeloencephalitis in a two-month-old colt","volume":"149","author":"Gray","year":"2001","journal-title":"Vet Rec"},{"issue":"3\u20134","key":"10.1016\/j.cveq.2016.12.001_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.vetpar.2014.02.055","article-title":"Sarcocystis neurona schizonts-associated encephalitis, chorioretinitis, and myositis in a two-month-old dog simulating toxoplasmosis, and presence of mature sarcocysts in muscles","volume":"202","author":"Dubey","year":"2014","journal-title":"Vet Parasitol"},{"issue":"1\u20132","key":"10.1016\/j.cveq.2016.12.001_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.vetpar.2013.10.001","article-title":"Serological status of mares in parturition and the levels of antibodies (IgG) against protozoan family Sarcocystidae from their pre colostral foals","volume":"199","author":"Pivoto","year":"2014","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.cveq.2016.12.001_bib7","first-page":"1359","article-title":"Equine protozoal myeloencephalitis","volume":"14","author":"MacKay","year":"1992","journal-title":"Compend Contin Educ Pract Vet"},{"issue":"2","key":"10.1016\/j.cveq.2016.12.001_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jvim.13834","article-title":"Equine protozoal myeloencephalitis: an updated consensus statement with a focus on parasite biology, diagnosis, treatment, and prevention","volume":"30","author":"Reed","year":"2016","journal-title":"J\u00a0Vet Intern Med"},{"issue":"4","key":"10.1016\/j.cveq.2016.12.001_bib9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2460\/javma.242.4.482","article-title":"Current therapeutic approaches to equine protozoal myeloencephalitis","volume":"242","author":"Dirikolu","year":"2013","journal-title":"J\u00a0Am Vet Med Assoc"},{"key":"10.1016\/j.cveq.2016.12.001_bib10","first-page":"8","article-title":"Equine protozoal myeloencephalitis","volume":"19","author":"Kisthardt","year":"1997","journal-title":"Equine Pract"},{"key":"10.1016\/j.cveq.2016.12.001_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-4017(99)00020-5","article-title":"Determination of activity of pyrimethamine, trimethoprim, sulfonamides, and combinations of pyrimethamine and sulfonamides against Sarcocystis neurona in cell cultures","volume":"82","author":"Lindsay","year":"1999","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.cveq.2016.12.001_bib12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2460\/ajvr.1983.44.04.540","article-title":"Trimethoprim-sulfadiazine in the horse: serum, synovial, peritoneal, and urine concentrations after single-dose intravenous administration","volume":"44","author":"Brown","year":"1983","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.cveq.2016.12.001_bib13","unstructured":"Reed SM, Saville WJ. Equine protozoal encephalomyelitis. Proceedings of 1996 Veterinary Symposium. American Association of Equine Practitioners. Denver, December 8\u201311, 1996."},{"key":"10.1016\/j.cveq.2016.12.001_bib14","first-page":"1599","article-title":"Treatment of equine protozoal myeloencephalitis","volume":"13","author":"Welsch","year":"1991","journal-title":"Compend Contin Educ Pract Vet"},{"key":"10.1016\/j.cveq.2016.12.001_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2460\/javma.1998.212.05.697","article-title":"Congenital defects in newborn foals of mares treated for equine protozoal myeloencephalitis during pregnancy","volume":"212","author":"Toribio","year":"1998","journal-title":"J\u00a0Am Vet Med Assoc"},{"key":"10.1016\/j.cveq.2016.12.001_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2460\/javma.1999.215.09.1317","article-title":"Measurements of reproductive function in stallions treated with trimethoprim-sulfamethoxazole and pyrimethamine","volume":"215","author":"Bedford","year":"1999","journal-title":"J\u00a0Am Vet Med Assoc"},{"key":"10.1016\/j.cveq.2016.12.001_bib17","unstructured":"Granstrom DE, McCrillis S, Wulff-Strobel C, et\u00a0al. Diclazuril and equine protozoal myeloencephalitis. Proceedings of 1997 Veterinary Symposium. American Association of Equine Practitioners. Phoenix, December 7\u201310, 1997."},{"key":"10.1016\/j.cveq.2016.12.001_bib18","unstructured":"Tobin T, Dirikolu L, Harkins JD, et\u00a0al. Preliminary pharmacokinetics of diclazuril and toltrazuril in the horse. Proceedings of 1997 Veterinary Symposium. American Association of Equine Practitioners. 1996."},{"key":"10.1016\/j.cveq.2016.12.001_bib19","unstructured":"Granstrom DE, Tobin T. Formulations and methods to treat and prevent equine protozoal myeloencephalitis. US patent 5,883,095. March 16, 1999."},{"key":"10.1016\/j.cveq.2016.12.001_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00937111","article-title":"Parasitic apicomplexans harbor a chlorophyll a-D1 complex, the potential target for therapeutic triazines","volume":"81","author":"Hackstein","year":"1995","journal-title":"Parasitol Res"},{"key":"10.1016\/j.cveq.2016.12.001_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2885.1999.00232.x","article-title":"Diclazuril in the horse: its identification detection and preliminary pharmacokinetics","volume":"22","author":"Dirikolu","year":"1999","journal-title":"J\u00a0Vet Pharmacol Ther"},{"key":"10.1016\/j.cveq.2016.12.001_bib22","first-page":"232","article-title":"Cerebrospinal fluid and serum concentrations of ponazuril in horses","volume":"2","author":"Furr","year":"2001","journal-title":"Vet Ther"},{"key":"10.1016\/j.cveq.2016.12.001_bib23","unstructured":"Reed SM, Wendel M, King S, et\u00a0al. Pharmacokinetics of ponazuril in horses. Proceedings of 2012 Veterinary Symposium. American Association of Equine Practitioners. Anaheim (CA): December 1\u20135, 2012."},{"key":"10.1016\/j.cveq.2016.12.001_bib24","first-page":"975","article-title":"Equine protozoal myeloencephalitis (EPM): Review of a diagnostic approach","volume":"21","author":"Bentz","year":"1999","journal-title":"Compend Contin Educ Pract Vet"},{"key":"10.1016\/j.cveq.2016.12.001_bib25","first-page":"258","article-title":"Diclazuril and equine protozoal myeloencephalitis (EPM): a clinical report","volume":"2","author":"Bentz","year":"2000","journal-title":"Equine Vet Educ"},{"key":"10.1016\/j.cveq.2016.12.001_bib26","first-page":"52","article-title":"New therapeutic approaches to equine protozoal myelo-encephalitis: pharmacokinetics of diclazuril sodium salts in the horse","volume":"7","author":"Dirikolu","year":"2006","journal-title":"Vet Ther"},{"key":"10.1016\/j.cveq.2016.12.001_bib27","first-page":"1","article-title":"Decoquinate combined with levamisole reduce the clinical signs and serum SAG 1,5,6 antibodies in horses with suspected equine protozoal myeloencephalitis","volume":"10","author":"Ellison","year":"2012","journal-title":"Intern J App Res Vet Med"},{"issue":"18","key":"10.1016\/j.cveq.2016.12.001_bib28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/vr.138.18.434","article-title":"Decoquinate and the control of experimental ovine toxoplasmosis","volume":"138","author":"Buxton","year":"1996","journal-title":"Vet Rec"},{"key":"10.1016\/j.cveq.2016.12.001_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S0031182005009108","article-title":"Immunomodulatory effect of various anti-parasitics: a review","volume":"132","author":"Sajid","year":"2006","journal-title":"Parasitol"},{"issue":"8","key":"10.1016\/j.cveq.2016.12.001_bib30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/2046-0481-63-8-498","article-title":"Pemoline and tetramisole \u2018positives\u2019 in English racehorses following levamisole administration","volume":"63","author":"Gutierrez","year":"2010","journal-title":"Ir Vet J"},{"key":"10.1016\/j.cveq.2016.12.001_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1645\/0022-3395(2006)92[637:PAOPRC]2.0.CO;2","article-title":"Prophylactic administration of ponazuril reduces clinical signs and delays seroconversion in horses challenged with Sarcocystis neurona","volume":"92","author":"Furr","year":"2006","journal-title":"J\u00a0Parasitol"},{"issue":"8","key":"10.1016\/j.cveq.2016.12.001_bib32","first-page":"54","article-title":"Prevention of equine protozoal myeloencephalitis","volume":"24","author":"Easter","year":"2007","journal-title":"Vet Forum"},{"key":"10.1016\/j.cveq.2016.12.001_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2460\/ajvr.69.3.396","article-title":"Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses","volume":"69","author":"Mackay","year":"2008","journal-title":"Am J Vet Res"},{"issue":"3","key":"10.1016\/j.cveq.2016.12.001_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvp.12176","article-title":"Pharmacokinetics of a low dose and FDA-labeled dose of diclazuril administered orally as a pelleted topdressing in adult horses","volume":"38","author":"Hunyadi","year":"2015","journal-title":"J\u00a0Vet Pharmacol Ther"},{"key":"10.1016\/j.cveq.2016.12.001_bib35","first-page":"215","article-title":"Efficacy of ponazuril 15% oral paste as a treatment for equine protozoal myeloencephalitis","volume":"2","author":"Furr","year":"2001","journal-title":"Vet Ther"},{"issue":"5","key":"10.1016\/j.cveq.2016.12.001_bib36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1645\/GE-67R","article-title":"Protective immune response to experimental infection with Sarcocystis neurona in 57BL\/6 mice","volume":"89","author":"Witonsky","year":"2003","journal-title":"J\u00a0Parasitol"},{"key":"10.1016\/j.cveq.2016.12.001_bib37","first-page":"223","article-title":"Safety of ponazuril 15% oral paste in horses","volume":"2","author":"Kennedy","year":"2001","journal-title":"Vet Ther"},{"key":"10.1016\/j.cveq.2016.12.001_bib38","unstructured":"US FDA. Protazil antiprotozoal pellets. 1.56% diclazuril. Freedom of Information Summary. Original new animal drug application. NADA 141\u2013268. Available at:\u00a0www.fda.gov\/downloads\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/FOIADrugSummaries\/ucm02320.pdf. Accessed July 7, 2016."},{"issue":"2","key":"10.1016\/j.cveq.2016.12.001_bib39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tvjl.2015.07.018","article-title":"Daily feeding of diclazuril top dress pellets in foals reduces seroconversion to Sarcocystis neurona","volume":"206","author":"Pusterla","year":"2015","journal-title":"Vet J"}],"container-title":["Veterinary Clinics of North America: Equine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749073916300840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749073916300840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:16:21Z","timestamp":1760069781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749073916300840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0749073916300840"],"URL":"https:\/\/doi.org\/10.1016\/j.cveq.2016.12.001","relation":{},"ISSN":["0749-0739"],"issn-type":[{"type":"print","value":"0749-0739"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutics for Equine\u00a0Protozoal Myeloencephalitis","name":"articletitle","label":"Article Title"},{"value":"Veterinary Clinics of North America: Equine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cveq.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}